Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca Silbermann

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|September 16, 2018
Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No CardiotoxicityStephen B Heitner, Jessica Minnier, Aynun Naher, et al.
Blood|April 7, 2025
Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myelomaSmith Giri, Binod Dhakal, Natalie S Callander, et al.
Blood Cancer Journal|February 5, 2025
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapyLuciano J Costa, Eva Medvedova, Binod Dhakal, et al.
Blood|January 27, 2026
Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapySusan Bal, Gayathri Ravi, Binod Dhakal, et al.
JCO Precision Oncology|July 12, 2021
High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple MyelomaDavid G Coffey, Andrew J Cowan, Bret DeGraaff, et al.
Journal of Hematology & Oncology|October 6, 2018
Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesisDaniela N Petrusca, Denise Toscani, Feng-Ming Wang, et al.
Future Oncology (London, England)|February 13, 2023
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myelomaBarry Paul, Michaela Liedtke, Jack Khouri, et al.
The Lancet. Haematology|September 30, 2023
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trialLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2021
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple MyelomaLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
Blood Cancer Journal|October 6, 2025
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analysesLaahn Foster, Larry D Anderson, Alfred Chung, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Clinical Lymphoma, Myeloma & Leukemia|September 16, 2018
Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No CardiotoxicityStephen B Heitner, Jessica Minnier, Aynun Naher, et al.
Blood|April 7, 2025
Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myelomaSmith Giri, Binod Dhakal, Natalie S Callander, et al.
Blood Cancer Journal|February 5, 2025
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapyLuciano J Costa, Eva Medvedova, Binod Dhakal, et al.
Blood|January 27, 2026
Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapySusan Bal, Gayathri Ravi, Binod Dhakal, et al.
JCO Precision Oncology|July 12, 2021
High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple MyelomaDavid G Coffey, Andrew J Cowan, Bret DeGraaff, et al.
Journal of Hematology & Oncology|October 6, 2018
Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesisDaniela N Petrusca, Denise Toscani, Feng-Ming Wang, et al.
Future Oncology (London, England)|February 13, 2023
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myelomaBarry Paul, Michaela Liedtke, Jack Khouri, et al.
The Lancet. Haematology|September 30, 2023
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trialLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2021
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple MyelomaLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
Blood Cancer Journal|October 6, 2025
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analysesLaahn Foster, Larry D Anderson, Alfred Chung, et al.
Pageof 5